Versed News and Research

RSS

Versed is a drug used to treat anxiety and tension and to relax muscles. It is also being studied in the treatment of nausea and vomiting caused by some cancer treatments. It is a type of benzodiazepine. Also called midazolam and midazolam hydrochloride.

Study: Repeat sternotomy for surgical aortic valve replacement safe for octogenarian patients

Surgical aortic valve replacement generally improves patients' symptoms and prolongs survival. However, the perceived risk of surgical aortic valve replacement in patients over 80 may result in surgery being denied or a recommendation for alternative therapy. Investigators at the Mayo Clinic challenge the way these patients have been managed.

29 Mar 2014

Novozymes Biopharma partners with Almac to provide combined service for drug development

Novozymes Biopharma, part of Novozymes A/S, a world leader in bioinnovation, is delighted to announce its new collaboration with Almac, to provide a combined service for drug development applications in the field of drug targeting and pharmacokinetic improvements.

22 Oct 2013

Viewpoints: 'Death throes' of health law opponents; Ryan's plan on entitlements may offer way out of budget crisis

Politically, the biggest challenges facing the ACA are behind us. By my count, the law has already survived three near-death experiences: the Democrats' loss of a filibuster-proof Senate majority with the election of Scott Brown in Jan. 2010, the Supreme Court's June 2012 decision upholding (with one exception) the law's constitutionality, and President Obama's re-election last Nov. Much of what we see going on in Washington now is the death throes of the opposition, especially now that Americans are beginning to sign up for coverage (John McDonough, 10/9).

11 Oct 2013

Radiofrequency ablation leads to remission of dysplastic Barrett's esophagus

Radiofrequency ablation (RFA) leads to remission for 91 percent of patients with dysplastic Barrett's esophagus, according to new figures published in Clinical Gastroenterology and Hepatology, the official clinical practice journal of the American Gastroenterological Association.

3 Oct 2013

FDA approves sNDA for SUSTIVA for treatment of HIV-1 infected pediatric patients

Bristol-Myers Squibb Company today announced that the U.S. Food and Drug Administration has approved a supplemental new drug application for SUSTIVA (efavirenz), including dosing recommendations for HIV-1 infected pediatric patients three months to three years old and weighing at least 3.5 kg.

4 May 2013

Roundup: Feds cut N.Y. Medicaid payments $1.2B; 93,000 fewer kids enroll in CHIP in Pa.; W. Va. lawmakers promise miners benefits

Federal authorities have dramatically lowered the amount that New York state can claim from the federal government for certain medical services, costing the state an estimated $1.2 billion.

3 Apr 2013

Forty percent of vets have little understanding of benefits due them

More than half of America's veterans say they have little or no understanding of the benefits due them, despite efforts over recent years to match returning soldiers with the help and services they need. An analysis of Department of Veterans Affairs survey data found that younger veterans – those who served in the post-9/11 war period – are better versed in their benefits.

21 Nov 2012

Michigan State University to improve food security and nutrition in Africa and Asia

Michigan State University will use a $7.3 million federal grant to cultivate the next generation of agricultural scientists in Africa and Asia, in hopes of improving food security and nutrition there.

7 Aug 2012

Longer looks: Alzheimer's researcher turns to drug she helped invent

Given her relatively young age, Dr. Rae Lyn Burke didn't think much about her family history of Alzheimer's disease -- a grandmother and an aunt had suffered from it, but they were much older. Ironically, Burke was just in her late 50s when she started having her own symptoms of early onset Alzheimer's. Even more ironic is that Burke had been one of the key developers of the Alzheimer's drug bapineuzumab, which she now takes herself to reduce the progression of the disease in her own brain.

22 Jun 2012

C-section rates in US stabilize after eight years of steady increase

A new report on trends in women's health in the United States reveals the national C-section rate has held steady at 33 percent since 2009, leveling off after eight years of steady increase that was in part driven by scheduled, elective surgeries and a trend for increasing the repeat C-section.

19 Jun 2012

Football-related brain injuries appear to rise among high school students

Catastrophic brain injuries associated with full-contact football appear to be rising, especially among high school students, according to a new report.

17 Apr 2012

News briefs from featured presentations at Cardiology 2012

Pediatric cardiology researchers and clinicians from almost 50 centers from across the U.S. and around the world are gathering at the Cardiology 2012 Conference sponsored by The Children's Hospital of Philadelphia on Feb. 22-26 in Orlando, Fla.

27 Feb 2012

Autism Speaks releases two new ATN tool kits

Autism Speaks, North America's leading autism science and advocacy organization, today released the Sleep Strategies for Children with Autism: A Parent's Guide and Treating Children with Autism Spectrum Disorders: A Tool Kit for Dental Professionals, both available for free download on Autism Speaks Tools You Can Use webpage.

22 Feb 2012

African-American children tend to be diagnosed later for autism

The rate of diagnosis for autism spectrum disorders (ASD) is the same among all racial groups — one in 110, according to current estimates. However, a study by a Florida State University researcher has found that African-American children tend to be diagnosed later than white children, which results in a longer and more intensive intervention.

16 Feb 2012

Gilead, Bristol-Myers Squibb to develop and commercialize fixed-dose combination for HIV

Bristol-Myers Squibb Company and Gilead Sciences, Inc. today announced a licensing agreement for Bristol-Myers Squibb to develop and commercialize a fixed-dose combination containing Bristol-Myers Squibb's protease inhibitor REYATAZ (atazanavir sulfate) and Gilead's cobicistat, a pharmacoenhancing or "boosting" agent that increases blood levels of certain HIV medicines to potentially allow for one pill once daily dosing.

27 Oct 2011

Dallas Children's administrator speaks at Chicago healthcare conference

Nationally acclaimed Studer Group, a private health care consulting firm, has chosen David Biggerstaff, vice president and administrator of Dallas Children's Medical Center at Legacy, to lead a comprehensive session at its ninth annual "What's Right in Health Care" conference in Chicago, Oct. 19 through 21.

20 Oct 2011

JU launches new curriculum for online RN to BSN degree program

Registered nurses choosing to complete a bachelor's degree need a program that prepares them to take leadership roles within their organizations. To address this need, U.S.News & World Report-ranked Jacksonville University (JU) is launching a new curriculum for its online RN to BSN degree program.

1 Oct 2011

Converting genetic data into biomedical knowledge a true challenge for statisticians

Within a decade, a combination of advanced measurement techniques and statistics will enable scientists to develop methods to diagnose serious diseases caused by genetic defects. Ten years after that, there may be medicines available to repair these defects.

21 Sep 2011

UT Southwestern surgeons to perform first hand transplant in North Texas

A team of surgeons at UT Southwestern Medical Center expects to perform the first hand transplant in North Texas within a year, making the institution just the sixth hospital in the U.S. to perform the rare and intricate surgery.

30 Aug 2011

Merck's VICTRELIS receives European CHMP positive opinion for treatment of chronic HCV genotype 1 infection

Merck, today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion under accelerated assessment recommending approval of the investigational medicine VICTRELIS (boceprevir) for the treatment of chronic hepatitis C virus genotype 1 infection, in combination with peginterferon alfa and ribavirin, in adult patients with compensated liver disease who are previously untreated or who have failed previous therapy.

20 May 2011